A single site, open-label phase I trial of NDI 010976 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2016
At a glance
- Drugs GS 0976 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nimbus Therapeutics
- 04 Apr 2016 According to a Gilead Sciences media release, the results of this trial will be presented at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).
- 24 Apr 2015 New trial record